Ventfort
- Category
- Bioregulators
- Administration routes
- Oral
- Regulatory status
- Not FDA-approved
A bioregulator peptide complex derived from blood vessel tissue, marketed to support vascular wall integrity and elasticity as vessels age. The case is speculative: claimed benefits for lipid profiles, atherosclerotic vessel function, and senile purpura rest on limited data, with only low-confidence signal on blood flow from related bioregulator work. Human safety data is thin. Not an approved drug in the US; supply is mostly research-grade product.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Ventfort is a natural peptide bioregulator containing a complex of low-molecular-weight peptides (up to 10,000 Da) extracted from vascular (aorta) tissue of young calves. Developed by Professor Vladimir Khavinson, it belongs to the Cytomaxes class and targets the vascular system, where it is designed to improve trophism of vascular wall cells, regulate metabolic processes in blood vessels, normalize cholesterol and lipoprotein levels, and reduce the risk of various vascular defects.
Clinical studies at the St. Petersburg Institute tested Ventfort in 49 patients with arterial atherosclerosis and senile purpura (ages 52-84). The treatment group (27 patients) received Ventfort plus standard therapy, while the control group (22 patients) received standard therapy alone. The report describes lower cholesterol and improved senile purpura; significant superiority over drugs alone was not demonstrated. A related PubMed study (PMID 25051774) evaluated the vasoactive tripeptide Vezugen (synthetic counterpart) in 41 patients with vasculogenic erectile dysfunction, showing significant improvement in penile blood flow.
Ventfort is positioned as one of the core cardiovascular bioregulators in Khavinson's anti-aging system.
How it works in the body
A bioregulator peptide complex derived from blood vessel tissue. It targets vascular smooth muscle and endothelial cells to regulate genes involved in elastin and collagen synthesis, maintaining blood vessel wall integrity and elasticity during aging.
Research overview
Ventfort has a formal clinical study report from the Khavinson Institute testing 49 patients (27 treatment, 22 control) with atherosclerosis and senile purpura. Ventfort patients had a significant total cholesterol reduction from baseline and numerical VLDL and triglyceride reductions for which statistical significance was not reported, with improved capillary resistance on the Hess test. A related study (PMID 25051774) on the synthetic vascular tripeptide Vezugen showed improved blood flow in erectile dysfunction. The broader Khavinson research provides mechanistic data on how vascular peptides regulate endothelial function and lipid metabolism.
Who researches Ventfort?
Commonly researched by
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(2)
Rated by level of concern
Allergic reaction to bovine vascular-derived peptides
LowClass-based inference; no product-specific safety publication found (PubMed 'Ventfort' = no results) — https://pubmed.ncbi.nlm.nih.gov/?term=Ventfort
Potential interaction with anticoagulants
TheoreticalPMID 31228385 (Adv Gerontol 2019; abstract explicitly cites effects on vessel/thrombocytary hemostasis, coagulability, fibrinolysis, kallikrein-kinin system) — https://pubmed.ncbi.nlm.nih.gov/31228385/
Interaction summary(8)
Rated by direction with this peptide
Warfarin and other vitamin K antagonists
CautionTheoreticalPreclinical reports that the vessel polypeptide complex modulates coagulation and fibrinolysis make an additive anticoagulant effect conceivable; no human PK/PD or INR data exist, so monitor INR rather than assume safety.
PMID 31228385 (hemostasis/coagulation/fibrinolysis effects) — https://pubmed.ncbi.nlm.nih.gov/31228385/
Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran)
CautionTheoreticalSame mechanistic concern as with warfarin — claimed effects on hemostasis and fibrinolysis could in principle add to DOAC anticoagulation, though nothing has been demonstrated in humans and no INR-equivalent monitoring exists.
PMID 31228385 (hemostasis/coagulation/fibrinolysis effects) — https://pubmed.ncbi.nlm.nih.gov/31228385/
Antiplatelet agents (aspirin, clopidogrel)
CautionTheoreticalThe animal-model claim of altered platelet hemostasis raises a theoretical additive bleeding risk when used with antiplatelet therapy; no case reports or trial data support an actual interaction.
PMID 31228385 (thrombocytary hemostasis effect) — https://pubmed.ncbi.nlm.nih.gov/31228385/
Statins (atorvastatin, rosuvastatin)
SynergisticTheoreticalBoth act on the atherosclerotic vessel wall by different routes — statins on LDL and plaque inflammation, KED-family peptides on endothelin-1, connexin and E-selectin expression in vitro — so co-use is plausibly complementary with no known pharmacokinetic conflict.
PMID 28539025 (endothelin-1/connexin) — https://pubmed.ncbi.nlm.nih.gov/28539025/ ; PMID 25408528 (E-selectin reduction by short peptides) — https://pubmed.ncbi.nlm.nih.gov/25408528/
Antihypertensives (ACE inhibitors, ARBs, calcium channel blockers)
CautionTheoreticalRat work in spontaneously hypertensive and aged hypertensive animals shows vasoactive and cerebral-microcirculation effects with cumulative dosing, so a modest additive blood-pressure or perfusion effect cannot be excluded; check BP when starting.
PMID 29322732 (Slavinorm, cerebral microcirculation in spontaneously hypertensive rats, cumulative dosing) — https://pubmed.ncbi.nlm.nih.gov/29322732/ ; PMID 28968027 (Slavinorm, cerebral microcirculation in old hypertensive rats) — https://pubmed.ncbi.nlm.nih.gov/28968027/
PDE5 inhibitors (sildenafil, tadalafil)
SynergisticTheoreticalThe one human report in this family used the KED analog Vezugen to improve penile arterial flow in atherosclerotic erectile dysfunction — the same endpoint PDE5 inhibitors target — so effects may be complementary, but the study was open-label monotherapy and no combination has been tested.
PMID 25051774 (Vezugen, penile-artery flow in 41 men) — https://pubmed.ncbi.nlm.nih.gov/25051774/
Bovine-protein allergy / alpha-gal syndrome
CautionModerateNot a drug interaction but the most concrete clinical contraindication: the product is a calf-vessel tissue extract, so people with documented bovine protein allergy or alpha-gal sensitization should avoid it absent purity documentation.
Product-composition-based; no safety publication indexed — https://pubmed.ncbi.nlm.nih.gov/?term=Ventfort
Other Khavinson-family bioregulators (Vezugen, Thymalin, Cortexin)
NeutralTheoreticalNo adverse interaction with these bioregulators has been reported, but combined use has had no controlled evaluation — absence of evidence, not evidence of safety.
No primary source documents combined bioregulator use.
Known risks(2)
Allergic reaction to bovine vascular-derived peptides
LowNo adverse events reported in clinical studies.
Potential interaction with anticoagulants
Low to ModerateVascular-targeting peptides could theoretically affect clotting; monitor if on anticoagulants.
Drug interactions(3)
Statins and lipid-lowering agents
Potential complementary effect; no documented interaction
Anticoagulants (warfarin, heparin, DOACs)
Theoretical vascular effects; monitor INR/coagulation if applicable
Antihypertensives
May have complementary vascular effects; monitor blood pressure
Research & benefits
Evidence base
- Evidence Level
- Limited Evidence
- Total Studies
- 4
- Human Studies
- 90
Ventfort has a formal clinical study with 49 patients showing improved lipid profiles and vascular function. The related synthetic peptide Vezugen has a PubMed-indexed study showing blood flow improvements. Together these provide modest supporting evidence, but studies are single-center, open-label, and have not been replicated outside Russia.
Researched for(4)
Rated by confidence in the evidence
Improved lipid profile (cholesterol, VLDL, triglycerides)
SpeculativeA small institute report describes human Ventfort results, but provides weak evidence.
PMID 31228385 (Adv Gerontol 2019, Kuznik/Ryzhak/Khavinson) — https://pubmed.ncbi.nlm.nih.gov/31228385/ (review of Slavinorm/Vasolin calf-vessel complex; the abstract states it normalizes lipid metabolism and prevents atherosclerosis in animal models)
Improved vascular wall function in atherosclerosis
SpeculativeCell and tissue-culture studies on the related KED tripeptide show vascular effects; no human data yet.
PMID 28539025 (Adv Gerontol 2016: KED tripeptide normalized endothelin-1 and restored connexin/sirtuin-1 expression in atherosclerotic and restenotic endothelial cultures; https://pubmed.ncbi.nlm.nih.gov/28539025/) and PMID 25408528 (Bull Exp Biol Med 2014, Khavinson lab: same KED tripeptide, indexed there under its internal code T-38 alongside the unrelated dipeptide RR-1, reduced E-selectin and normalized Ki-67/p53 in aged vascular cell cultures; https://pubmed.ncbi.nlm.nih.gov/25408528/). Both studies are cell/tissue-culture work on the synthetic KED tripeptide (marketed separately as Vesugen), not on Ventfort's cruder tissue-extract formulation itself, and neither includes human outcome data.
Improvement in senile purpura
SpeculativeA small institute report describes improved capillary resistance and fewer bleeding spots; reliable confirmation is lacking.
No primary source identified; PubMed search for 'Ventfort' returns no results — https://pubmed.ncbi.nlm.nih.gov/?term=Ventfort
Vascular blood flow improvement (related Vezugen data)
LowOpen-label study in 41 men found improved artery flow using a related peptide, Vezugen.
PMID 25051774 (Adv Gerontol 2014; Vezugen, 41 men, penile-artery flow improved) — https://pubmed.ncbi.nlm.nih.gov/25051774/ ; PMID 27383168 (Bull Exp Biol Med 2016; Slavinorm raised cortical microvascular density in aged rats) — https://pubmed.ncbi.nlm.nih.gov/27383168/
Benefits(4)
Improved lipid profile (cholesterol, VLDL, triglycerides)
Khavinson Institute clinical study (49 patients)
Improved vascular wall function in atherosclerosis
Khavinson Institute clinical study
Improvement in senile purpura
Khavinson Institute clinical study (Hess test normalization)
Vascular blood flow improvement (related Vezugen data)
PMID 25051774 (41 patients, erectile dysfunction/atherosclerosis)
Key studies(2)
Clinical study of peptide bioregulator Ventfort
Open-label clinical studyn=27 treatment + n=22 control10-15 daysKhavinson VKh et al.
St. Petersburg Institute of Bioregulation and Gerontology (internal report)
2004
Total cholesterol decreased significantly from baseline; superiority over standard therapy and significant VLDL or triglyceride reductions were not demonstrated. Improvement in senile purpura (Hess test). No side effects reported.
The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people
Clinical studyn=41VariableKitachev KV, Sazonov AB, Kozlov KL, Petrov KIu, Sliusarev AS, Khavinson VKh
Advances in Gerontology
2014
Vasoactive tripeptide Vezugen significantly improved blood flow through the main penile artery in patients with vasculogenic erectile dysfunction as a manifestation of atherosclerosis.
Regulation & availability
Why researchers look at it
Ventfort targets vascular wall metabolism with organ-specific peptides from young calf aorta. It addresses atherosclerosis and vascular aging, with clinical data showing improved lipid profiles and a core role in Khavinson cardiovascular anti-aging protocols.
- Estimated cost
- $30-60/mo (capsules)
- FDA status
- Not FDA-approved; not reviewed by FDA; sold as dietary supplement internationally
- WADA status
- Not individually named. WADA S0 can prohibit unapproved pharmacological substances regardless of whether they are named. Obtain a product-specific anti-doping determination.
- Prescribability
- Available in Russia as dietary supplement; not approved in USA/EU
- Availability
- Manufactured by GARMONIA Ltd. Not available through conventional pharmacies in USA/EU.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(3)
- 2003-2004Clinical study conducted at St. Petersburg Institute (Nov 2003 - Feb 2004)
- 2000sCommercialized as Cytomaxes dietary supplement in Russia
- 2014Related Vezugen study published (PMID 25051774)
Sources & FAQs
Research sources(2)
Frequently asked questions(2)
Can Ventfort help with high cholesterol?
A small Russian study showed improved cholesterol, VLDL, and triglyceride levels. However, this is not sufficient evidence to recommend Ventfort as a cholesterol treatment. It should not replace prescribed statin or lipid-lowering medications.
How is Ventfort different from Vesugen?
Ventfort is a natural peptide complex (Cytomaxes) extracted from animal aorta tissue, while Vesugen is a synthetic tripeptide (Cytogen) targeting the vascular endothelium. Both target blood vessels but through different production methods.